PubMed Health⌕ Search

Biomedical subjects

KN Garratt

Publications and source records attributed to KN Garratt.

5 recordsLinked to original sources

Stable Angina Pectoris.

Patients with stable Canadian Heart Classification I or II angina pectoris may be managed successfully with a conservative medical program. Such a program should always include aspirin, beta-blocking agents, and lipid-lowering therapies unless contraindications to them exist. Exercise and dietary restrictions will achieve target lipid values in some patients; the remainder should be treated with a lipid-lowering drug if they are at high risk of cardiac events. Emerging data support a role for angiotensin-converting enzyme inhibitors in many, if not all, patients with coronary artery disease. The role of calcium antagonists in this population remains uncertain, with some favorable and some unfavorable effects seen with these agents. High-risk patients and those with a desire to achieve greater exercise tolerance once medical therapies have been optimized are suitable candidates for angiographic study and revascularization. Although randomized studies addressing this population are limited, available data support the benefits of either coronary artery bypass grafting or percutaneous catheter intervention.

Journal Article↗

Low Molecular Weight Heparin and Coronary Intervention.

For more than 25 years, basic experiments using cell culture and animal experimental techniques have predicted superior thrombin inhibition with use of low molecular weight heparin (LMWH) rather than unfractionated heparin (UFH). This should have application in the cardiac laboratory, where thrombin control is essential to securing a safe and optimal therapeutic angioplasty for patients with atherosclerotic heart disease. Despite much interest, few meaningful clinical studies have been completed and there are limited clinical data to establish the magnitude of benefit actually conferred through use of LMWH rather than UFH among most patients undergoing elective or urgent cardiac catheterization procedures. At this point, the available data suggest minimal clinical advantage is to be gained through the use of LMWH over UFH. Also, obtaining this modest advantage may require an extended period of drug therapy before and after intervention. Any benefit conferred is likely restricted to the period shortly after coronary intervention. On the other hand, available data suggest that serious bleeding should not be problematic despite difficulties measuring that antithrombin effect among patients receiving LMWH, even when it is combined with potent platelet inhibitor therapy. Although cell culture and animal experiments suggest that heparin compounds should be effective in limiting intimal hyperplasia (and therefore clinical restenosis) after angioplasty, randomized clinical trials have failed thus far to show any restenosis benefit for either UFH or LMWH. Ongoing studies will clarify the use of combining LMWH with potent antiplatelet agents as combined medical adjuncts to coronary intervention.

Journal Article↗

Catheter-Based Therapy for Saphenous Vein Bypass Graft Disease.

Improved patient survival and the limitations of repeat coronary artery surgery have generated a growing population of patients referred for catheter-based treatment of vein graft lesions. In this subject review, the current state of knowledge regarding therapeutic options for these difficult lesions is discussed. Despite improvements in technique and materials, risks of treatment with balloon angioplasty remain higher than for other lesion types. The underlying lesion pathology determines therapeutic risk to a large degree. Newer therapeutic alternatives appear to offer advantages over balloon angioplasty, but improved clinical outcomes have not been demonstrated in appropriate trials for most new devices and treatment strategies. On-going studies will clarify the utility of some new devices, and other studies are needed.

Journal Article↗